

NON-EXECUTIVE DIRECTOR RESIGNATION

Perth, Australia; 3 MARCH 2025 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other neurological conditions, today announces the resignation of Mr Rob Black as a Non-Executive Director of the Company, effective today.

Mr Black will be commencing a full-time executive position in the financial services sector effective 4th March 2025 and coupled with his other commitments, no longer has the capacity to continue as a Non-Executive Director.

The Board thanks Mr Black for his valuable contribution and wishes him well in his new role.

Authorised for release by the Board.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica is now undertaking a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.